Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The assessment of circulating tumor DNA associated with Wnt/ β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis
CONCLUSION: This study confirmed that Wnt/β-catenin signaling pathway-related ctDNA had the better diagnostic potential for liver cancer and might be an effective complementary tool for serum AFP assays in the early diagnosis of liver cancer.PROSPERO: (No. CRD42023404984).[Figure: see text].PMID:38299537 | DOI:10.1080/14737140.2024.2312246 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - February 1, 2024 Category: Cancer & Oncology Authors: Xingyuan Ma Zhe Wang Shuaiyang Wang Ye Tian Bei Xie Jing Li Bin Ma Linjing Li Source Type: research

Cancer immunotherapy efficacy and machine learning
Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):21-28. doi: 10.1080/14737140.2024.2311684. Epub 2024 Feb 12.ABSTRACTINTRODUCTION: Immunotherapy is one of the major breakthroughs in the treatment of cancer, and it has become a powerful clinical strategy, however, not all patients respond to immune checkpoint blockade and other immunotherapy strategies. Applying machine learning (ML) techniques to predict the efficacy of cancer immunotherapy is useful for clinical decision-making.AREAS COVERED: Applying ML including deep learning (DL) in radiomics, pathomics, tumor microenvironment (TME) and immune-related genes analysis to...
Source: Expert Review of Anticancer Therapy - January 30, 2024 Category: Cancer & Oncology Authors: Yuting Fang Xiaozhong Chen Caineng Cao Source Type: research

Safety and efficacy of Rucaparib in the treatment of ovarian cancer and patients with BRCA mutation: a systematic review and meta-analysis of phase III randomized clinical trials
CONCLUSION: Rucaparib demonstrated significant efficacy in improving PFS and ORR in ovarian cancer patients, particularly those having BRCA mutations. However, they should be closely monitored due to the greater risk of various adverse effects.PMID:38252024 | DOI:10.1080/14737140.2024.2309177 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - January 22, 2024 Category: Cancer & Oncology Authors: Mus'ab Theeb Mustafa Aws Khalid Abushanab Mahmoud Taysir Mousa Rana Ahmed Qawaqzeh Hamza Muneer Alakhras Ahmad Sami Othman Ahmad Sa'ed Source Type: research

LncRNA < em > HCG11 < /em > enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis
CONCLUSIONS: This study provides a reference for investigating the potential value of lncRNA HCG11 in the diagnosis of NSCLC and finding potential targets against clinical chemotherapeutic resistance in NSCLC.PMID:38230690 | DOI:10.1080/14737140.2024.2305352 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - January 17, 2024 Category: Cancer & Oncology Authors: Yufen Xu Xiaoli Tan Qi Yang Zhixian Fang Wenyu Chen Source Type: research

Considerations regarding maintenance therapy for acute myeloid leukemia in remission
Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):15-20. doi: 10.1080/14737140.2024.2306164. Epub 2024 Feb 12.ABSTRACTINTRODUCTION: For most adult patients with acute myeloid leukemia, relapse is characteristic of the disease. When allotransplant in first complete remission is administered as consolidative therapy, relapse is still common, affecting 20-40% of recipients. Maintenance of remission with low-dose treatments may hold promise in preventing relapse.AREAS COVERED: Improvements in the detection of clinical and biological variants of disease allow the practitioner to identify which patients, based on disease features...
Source: Expert Review of Anticancer Therapy - January 17, 2024 Category: Cancer & Oncology Authors: Gary J Schiller Vlad Kustanovich Source Type: research

Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Expert Rev Anticancer Ther. 2024 Jan-Feb;24(1-2):41-58. doi: 10.1080/14737140.2024.2305356. Epub 2024 Feb 12.ABSTRACTINTRODUCTION: Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of cutaneous T-cell lymphoma. Although many available treatments offer temporary disease control, allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only curative treatment option for advanced stage MF and SS. CAR T-cell therapy is a promising new avenue for treatment.AREAS COVERED: In this review, we discuss the evidence supporting the use of allo-HSCT for the treatment of MF/SS, including disease status at...
Source: Expert Review of Anticancer Therapy - January 15, 2024 Category: Cancer & Oncology Authors: Amrita Goyal Francine Foss Source Type: research

Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with < em > BRCA < /em > mutational status: a systematic review and network meta-analysis
CONCLUSION: All PARPis showed significant benefit, with olaparib showing greater benefit in newly diagnosed and PSR OC women.REGISTRATION: CRD42021288932.PMID:38174379 | DOI:10.1080/14737140.2023.2298832 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - January 4, 2024 Category: Cancer & Oncology Authors: Shulin Zhou Yi Jiang Chengyan Luo Lin Yuan Source Type: research

Circadian rhythm-based cancer therapy in randomised clinical trials
Expert Rev Anticancer Ther. 2023 Dec 21:1-11. doi: 10.1080/14737140.2023.2298835. Online ahead of print.ABSTRACTINTRODUCTION: Since the 2017 Nobel Prize awarded to J. Hall, M. Rosbash and M.W. Young for their discoveries of molecular mechanisms behind the biological clock, circadian rhythm-based therapy, also known as chronotherapy, is receiving more attention in oncology and the number of anatomical sites of interest in this field is increasing. This observation is in line with the clinical evidence provided by trials on head and neck, lung, colorectal and cervical cancers, as well as the presently ongoing chronotherapy t...
Source: Expert Review of Anticancer Therapy - December 21, 2023 Category: Cancer & Oncology Authors: Loredana G Marcu Source Type: research